SEC Form 4 · accession 0001647994-26-000011
ImmunityBio, Inc. · IBRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barry J. Simon
Director
Period of report
Jun 24, 2026
Accepted (ET)
Jun 26, 2026 · 9:00 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001326110
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 24, 2026 | S | 25,000 | $7.8763 | D | 2,802,788 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 18, 2025.
- F2Represents the weighted average share price of an aggregate total of 25,000 shares sold in the price range of $7.875 to $7.885 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.